

METABASIS THERAPEUTICS INC

Form 8-K

July 17, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**Form 8-K**

**Current Report Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 17, 2007**

**Metabasis Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of  
incorporation)

**000-50785**

(Commission File Number)

**33-0753322**

(I.R.S. Employer  
Identification No.)

**11119 North Torrey Pines Road**

**La Jolla, California**

(Address of principal executive offices)

**92037**

(Zip Code)

Registrant's telephone number, including area code: **(858) 587-2770**

**Not Applicable.**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On July 17, 2007, we announced that we have been informed by our strategic collaborator, Daiichi Sankyo, of its initial review of results from a three-month Phase 2b clinical trial of CS-917 in patients with type 2 diabetes. In addition, we announced that we have been informed by Schering-Plough Corporation of its intention to terminate the agreements it entered into with Metabasis and Valeant Pharmaceuticals International in December 2006 for the development and commercialization of pradeфовir. The announcements were made in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.**

99.1 Press release of Metabasis Therapeutics, Inc. dated July 17, 2007.

2

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**METABASIS THERAPEUTICS, INC.**

By: */s/ John W. Beck*  
John W. Beck  
*Senior Vice President of Finance, Chief  
Financial Officer and Treasurer*

Date: July 17, 2007

**INDEX TO EXHIBITS**

99.1 Press release of Metabasis Therapeutics, Inc. dated July 17, 2007.

4

---